Answers are grounded in this paper and cite their sources.
T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. (Funded by F. Hoffmann-La Roche/Genentech; EMILIA ClinicalTrials.gov number, NCT00829166.).
No takes yet. Share an insight, caveat, or question.
Verma et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: